Exclusive Content > News
Coronavirus and Covid-19 Related Events
PeteS in CA:
Yeppers, China is handling this coronavirus so-o-o-o-oooooooo well!
Czech Republic rejected defective coronavirus tests from China: 3/26/2020, https://www.praguemorning.cz/80-of-rapid-covid-19-tests-the-czech-republic-bought-from-china-are-wrong/
Spain rejected defective coronavirus tests from Shenzhen Bioeasy Biotechnology: 3/26/2020, https://www.businessinsider.com/coronavirus-spain-says-rapid-tests-sent-from-china-missing-cases-2020-3
Turkey rejected defective sample coronavirus tests from Shenzhen Bioeasy Biotechnology: 3/27/2020, https://www.middleeasteye.net/news/coronavirus-turkey-faulty-chinese-kits-not-use
Georgia (nation) rejected defective coronavirus tests from Shenzhen Bioeasy Biotechnology: 3/27/2020, https://agenda.ge/en/news/2020/953
Slovakia rejected defective coronavirus tests from China: 4/1/2020, https://www.bloomberg.com/news/articles/2020-04-01/faulty-virus-tests-cloud-china-s-european-outreach-over-covid-19
UK rejected defective coronavirus tests from China: 4/6/2020, https://www.telegraph.co.uk/news/2020/04/06/government-seeks-refund-millions-coronavirus-antibody-tests/
Australia seizing defective masks and PPE from China: starting around 3/11/2020, https://www.abc.net.au/news/2020-04-01/coronavirus-chinese-ppe-border-force-intercepted/12085908
Netherlands rejected defective masks from China: 3/28/2020, https://www.bbc.com/news/world-europe-52092395
Austria rejected defective masks from China: 4/6/2020, https://www.diepresse.com/5796725/chinesische-schutzmasken-fur-sudtirol-waren-unbrauchbar (German language)
Canada rejected defective masks from China: 4/7/2020, https://torontosun.com/news/local-news/over-62000-defective-masks-sent-to-toronto-long-term-care-workers
Defective tests, defective PPE, but Chinese statistics are reliable? *****rollingeyes*****
PeteS in CA:
Over the past couple of months I'd added a few items to my US and China/WHO timelines without noting it by bumping this thread. Over the past couple of weeks I've been fitfully rooting through this Congressional Research Service report, and this AM I updated both timelines.
The additions to the US timeline give a fuller picture of things done in January, 2020 by the Trump Administration, more evidence of the ludicrous falseness of the Dems' and MSM's (I know, repetitive and redundant) Trump did nothing for 2 months narrative.
The additions to the China/WHO timeline were jaw-dropping for me. The bureaucratic cover-ups at all levels ... the attacks of doctors trying to do their jobs and warn their colleagues and communities ... the shutting down of unauthorized research, the multi-layered delays in communicating key information to the world (and only doing so after the key information was leaked to the West) ... outrageous.
At the same time, a picture emerges that Wuhan officials, Hubei Province officials, and national officials were very slow to take the organizational steps to fight the virus within China. Some of the Trump Administration's organizational actions preceded China's similar actions, and some followed China's by a few days. Before concluding that the Trump Administration was following as much as leading, keep in mind that in January what was then believed to be the first US Covid-19 case was diagnosed on January 20th; at that time China had hundreds of cases, and on that date China/WHO had finally admitted that human-human transmission had happened. In the context of what was known when, the Trump Administration was clearly leading. And in the context of the Dems' shampeachment, leading was politically risky.
PeteS in CA:
Other than the stat that this thread has had nearly 6400 Views, I don't know who viewed it when and how often. A good number of the Views are me, because I have updated the US and China timelines frequently and substantially, but haven't posted announcements for the updates. Today's update to the US timeline includes some key info to understanding the rather fast Covid-19 vaccine development and testing. Here are those key items and a couple of articles that expand on them:
February 6, 2017 - DARPA launched the Pandemic Prevention Platform, an effort to create a standardized process to create medical countermeasures to a viral outbreak within 60 days, preventing the outbreak from becoming a pandemic; https://www.darpa.mil/news-events/2017-02-06a
February 22, 2018 - DARPA names the research institutions that will be participating in DARPA's Pandemic Prevention Platform, launched in 2017; https://globalbiodefense.com/2018/02/22/stopping-pandemic-x-darpa-names-researchers-working-to-halt-outbreaks/
https://spectrum.ieee.org/the-human-os/biomedical/bionics/darpas-firebreak-treatment-for-the-coronavirus :
DARPA Races To Create a “Firebreak†Treatment for the Coronavirus
--- Quote ---When DARPA launched its Pandemic Preparedness Platform (P3) program two years ago, the pandemic was theoretical. It seemed like a prudent idea to develop a quick response to emerging infectious diseases. Researchers working under the program sought ways to confer instant (but short-term) protection from a dangerous virus or bacteria.
Today, as the novel coronavirus causes a skyrocketing number of COVID-19 cases around the world, the researchers are racing to apply their experimental techniques to a true pandemic playing out in real time. ...
...
Robert Carnahan, who works with Crowe at the Vanderbilt Vaccine Center ...
...
Jenkins says that all of the P3 groups (the others are Greg Semposki’s lab at Duke University, a small Vancouver company called AbCellera, and the big pharma company AstraZeneca[/b]) have made great strides in technologies that rapidly identify promising antibodies. ...
...
Moderna was involved in a related DARPA program known as ADEPT that has since ended. The company’s work on mRNA-based therapies has led it in another interesting direction—last week, the company made news with its announcement that it was testing an mRNA-based vaccine for the coronavirus.
--- End quote ---
DARPA's partners began working on vaccines in January 2020 as part of a program launched in 2017 and begun in 2018. AstraZeneca and Moderna are two of the three companies whose vaccines are in Phase III testing. AbCellera is partnered with Eli Lilly, and their antibody treatment is in Phase I testing, https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment .
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development
Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus
--- Quote ---CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and the Coalition for Epidemic Preparedness Innovations (CEPI), today announced a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV).
Under the terms of the agreement, Moderna will manufacture an mRNA vaccine against 2019-nCoV, which will be funded by CEPI. The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, collaborated with Moderna to design the vaccine. NIAID will conduct IND-enabling studies and a Phase 1 clinical study in the U.S.
--- End quote ---
https://www.abcellera.com/news/2020-01-abcellera-mobilizing-a-response-to-novel-coronavirus :
AbCellera is mobilizing a response to the novel coronavirus outbreak as part of its DARPA P3 program
--- Quote ---JANUARY 28, 2020
AbCellera confirms that it is mobilizing its pandemic response platform against the ongoing outbreak of a novel coronavirus (2019-nCoV) originating in Wuhan, China. Since 2018, under the DARPA Pandemic Prevention Platform (P3) program, AbCellera has been leading a team of partners to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera’s rapid, high-throughput therapeutic antibody discovery technology will be used to discover coronavirus-neutralizing antibodies that could ultimately be deployed to stop transmission of the 2019-nCoV outbreak.
--- End quote ---
IOW, our current state in which three vaccines are in the final stage of pre-authorization tests is the result of a DARPA (Defense Advanced Research Projects Agency) program launched in 2017 and begun in 2018. Of those three vaccines, at least two - AstraZeneca and Moderna - are from participants in DARPA's Pandemic Prevention Platform program, AstraZeneca and Moderna. Another participant, AbCellera (with partner Eli Lilly), has an antibody treatment in Phase I testing. Moderna and AbCellera both began their Covid-19 work under the aegis of that DARPA program in January, 2020.
PeteS in CA:
A note regarding including Clover Pharmaceuticals' vaccine candidate in the US timeline ... Clover is a Chinese company, and I have been ignoring Chinese vaccines for obvious reasons. However, Clover is partnering with two US companies, GlaxoSmithKline and Dynavax, which produce adjuvants. Adjuvants strengthen the effectiveness of vaccines, allowing smaller doses and more doses per batch. So these companies are participants in trials who have a financial stake in the testing being done properly. I think at least some of the testing is being done in Australia. A Canadian vaccine developer, Medicago, is also working with GSK and Dynavax.
LegalAmerican:
NICE.
Navigation
[0] Message Index
[#] Next page
[*] Previous page
Go to full version